Copeland Capital Management LLC Has $108.07 Million Stock Position in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Copeland Capital Management LLC boosted its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 1.0% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,163,392 shares of the medical instruments supplier's stock after acquiring an additional 11,318 shares during the quarter. LeMaitre Vascular comprises about 1.9% of Copeland Capital Management LLC's holdings, making the stock its 4th largest holding. Copeland Capital Management LLC owned approximately 5.18% of LeMaitre Vascular worth $108,068,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. Raymond James & Associates boosted its stake in shares of LeMaitre Vascular by 2.6% in the third quarter. Raymond James & Associates now owns 29,592 shares of the medical instruments supplier's stock valued at $2,749,000 after purchasing an additional 748 shares during the period. NBC Securities Inc. grew its position in shares of LeMaitre Vascular by 73.2% during the third quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier's stock worth $40,000 after buying an additional 183 shares in the last quarter. Creative Planning increased its position in shares of LeMaitre Vascular by 20.7% in the 3rd quarter. Creative Planning now owns 3,594 shares of the medical instruments supplier's stock worth $334,000 after purchasing an additional 617 shares during the last quarter. Annex Advisory Services LLC lifted its position in shares of LeMaitre Vascular by 4.6% during the third quarter. Annex Advisory Services LLC now owns 29,908 shares of the medical instruments supplier's stock worth $2,778,000 after purchasing an additional 1,318 shares during the last quarter. Finally, USA Financial Formulas acquired a new position in LeMaitre Vascular in the third quarter worth about $60,000. Institutional investors and hedge funds own 84.64% of the company's stock.

Insider Activity at LeMaitre Vascular

In other LeMaitre Vascular news, Director David B. Roberts sold 3,063 shares of the business's stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $82.07, for a total transaction of $251,380.41. Following the sale, the director now directly owns 14,114 shares in the company, valued at approximately $1,158,335.98. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 10.79% of the stock is currently owned by insiders.

LeMaitre Vascular Trading Down 1.5 %

LeMaitre Vascular stock traded down $1.35 during midday trading on Tuesday, reaching $87.27. 81,301 shares of the stock traded hands, compared to its average volume of 122,216. The firm has a fifty day moving average price of $89.03 and a two-hundred day moving average price of $81.77. LeMaitre Vascular, Inc. has a fifty-two week low of $44.27 and a fifty-two week high of $93.32. The firm has a market cap of $1.96 billion, a price-to-earnings ratio of 58.69, a PEG ratio of 2.45 and a beta of 0.88.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last issued its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $0.52 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.47 by $0.05. The business had revenue of $55.85 million during the quarter, compared to analyst estimates of $54.98 million. LeMaitre Vascular had a return on equity of 12.41% and a net margin of 18.33%. The business's revenue for the quarter was up 11.4% compared to the same quarter last year. During the same period in the prior year, the company posted $0.37 EPS. Analysts anticipate that LeMaitre Vascular, Inc. will post 1.85 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, August 29th. Investors of record on Thursday, August 15th were issued a $0.16 dividend. This represents a $0.64 annualized dividend and a yield of 0.73%. The ex-dividend date was Thursday, August 15th. LeMaitre Vascular's payout ratio is currently 42.38%.

Wall Street Analyst Weigh In

LMAT has been the subject of several research reports. Cantor Fitzgerald started coverage on LeMaitre Vascular in a research report on Tuesday, October 15th. They issued a "neutral" rating and a $96.00 target price for the company. JMP Securities boosted their target price on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the company a "market outperform" rating in a research note on Tuesday, August 20th. StockNews.com downgraded shares of LeMaitre Vascular from a "buy" rating to a "hold" rating in a research report on Tuesday, August 27th. Lake Street Capital began coverage on shares of LeMaitre Vascular in a research report on Friday, August 2nd. They set a "buy" rating and a $105.00 price objective for the company. Finally, Barrington Research reiterated an "outperform" rating and set a $92.00 price objective on shares of LeMaitre Vascular in a research note on Friday, September 20th. Three investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $94.67.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.